On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.
On February 14, 2013, the US Patent and Trademark Office (USPTO) released the relevant rules and associated guidelines pertaining to the ‘first inventor to file’ provisions of the America Invents Act (AIA). Th is article considers two sections of the new laws and associated rules and guidelines, which may particularly affect the life sciences industry and should be considered when conducting business.
Because of their reliance on investment funds, biotech companies often make public disclosures/press announcements regarding technology developments. In addition, the sale of technology is oft en important to life science companies. Th e following two sections of AIA 35 USC§102 will have important implications for the disclosure and/or sale of technology.
Sale of invention to create prior art
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AIA, FITF, prior art, USPTO